Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
2
100%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Other(1)

Detailed Status

Not yet recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

not_yet_recruiting150%
suspended150%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_2

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

NCT06229067
suspendedphase_2

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

NCT02897050

Clinical Trials (2)

Showing 2 of 2 trials
NCT06229067Phase 2

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Not Yet Recruiting
NCT02897050Phase 2

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Suspended

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2